The evolution of three decades of antiretroviral therapy: Challenges, triumphs and the promise of the future by Tseng, A. et al.
  
MURDOCH RESEARCH REPOSITORY 
 
 
 
 
This is the author’s final version of the work, as accepted for publication  
following peer review but without the publisher’s layout or pagination.  
The definitive version is available at 
 
 
http://dx.doi.org/10.1111/bcp.12403  
 
 
Tseng, A., Seet, J. and Phillips, E.J. (2014) The evolution of three decades of 
antiretroviral therapy: Challenges, triumphs and the promise of the future. 
British Journal of Clinical Pharmacology, 79 (2). pp. 182-194. 
 
 
 
http://researchrepository.murdoch.edu.au/24471/ 
 
 
 
 
 
Copyright: © 2014 The British Pharmacological Society 
It is posted here for your personal use. No further distribution is permitted. 
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
 
 
The Evolution of Three Decades of Antiretroviral Therapy: 
Challenges, Triumphs and the Promise of the Future
1
 
 
 
 
Alice Tseng
1,2
, Jason Seet
3
, Elizabeth J. Phillips
4,5 
 
 
1
University Health Network, Toronto, Canada 
 
2 
Leslie Dan Faculty of Pharmacy, University of Toronto, Canada
 
 
3
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia 
 
4
Vanderbilt University School of Medicine, Tennessee, USA 
 
5
Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, 
Western Australia 
 
 
 
Correspondence to: 
 
Dr. Elizabeth Phillips 
1161 – 21st Avenue South 
A-2200 Medical Center North 
Nashville, TN  37332-2582 
elizabeth.j.phillips@vanderbilt.edu 
 
 
 
Key words:  HIV, therapeutic drug monitoring, drug interactions, HLA, 
Pharmacogenomics, nanoformualation, adherence, antiretroviral, sanctuary site, 
eradication 
 
Summary 
 
The evolution of HIV treatment has improved our understanding and management of 
complex pharmacological issues that have driven improved outcomes and quality of 
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life of the HIV-infected patient.   These include adherence, long and short-term 
toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring 
(TDM), differential penetration of drugs into sanctuary sites such as the central 
nervous system (CNS), genital tract and small bowel and drug-drug and drug-food 
interactions related to cytochrome P450 drug metabolizing enzymes, UGT1A1 and 
drug transporters to name a few.  There is future promise as an increased 
understanding of the immunopathogenesis of HIV and global public health initiatives 
are driving novel treatment approaches with goals to prevent, control and ultimately 
eradicate HIV. 
 
Introduction:  The Evolution of HIV Treatment 
In less than 30 years of antiretroviral therapy (ART) there have been over 25 drugs 
developed (Figure 1).   In 1987 the first antiretroviral agent, zidovudine (AZT), a 
nucleoside reverse transcriptase inhibitor (NRTI) was shown to positively impact 
clinical progression and death [1].  Challenges of early NRTI regimens included high 
pill burdens, inconvenient dosing, treatment limiting toxicities and incomplete 
virologic suppression. Sequential monotherapy and incomplete virologic suppression 
resulted in emergence of multiple resistance mutations with long-term treatment 
consequences.   HIV protease inhibitors (PIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) introduced in the mid-1990s revolutionized the 
management of HIV infection. Highly active antiretroviral therapy (HAART) 
regimens consisting of two NRTIs plus a PI or NNRTI were capable of virologic 
suppression (<400 copies/ml), and widespread uptake quickly led to dramatic 
reductions in morbidity and mortality in the developed world [2].  The strategy of 
using two NRTIs plus a potent third agent still forms the cornerstone of current A
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treatment principles, and is now referred to as combination antiretroviral therapy 
(cART) (Table 1).  
 
Fluctuation in HIV treatment guidelines over the last two decades reflect the evolving 
challenges in this field (Figure 2).  In 1998 with new treatment optimism the mantra 
was “Hit hard, hit early”[3](Figure 2).   However, the challenges of HAART were 
soon realized: high pill burdens, inconvenient dosing, stringent food requirements, 
treatment limiting toxicities and numerous drug interactions.  Unrealistic levels of 
adherence (>95%) were required to maintain adequate ART exposure and maintain 
viral suppression [4, 5].  PIs were limited by unfavourable pharmacokinetic (PK) 
characteristics including limited oral bioavailability, short half-lives, significant inter- 
and intra-patient variability, propensity for drug interactions, risk of resistance, 
toxicity, and storage/stability issues. NNRTIs had the advantage of long half-lives, but 
disadvantages of toxicities, drug interactions and single mutation conferring high-
level class resistance.  
 
The ability to measure lower level viremia (<40 or 50 copies/ml) further highlighted 
the challenge of incomplete virologic suppression, particularly in treatment- 
experienced patients with multiple NRTI mutations. High pill burdens and the 
emergence and recognition of long-term and sometimes irreversible toxicities such as 
thymidine analogue (d4T/AZT) associated lipoatrophy led to further treatment fatigue 
and a backlash against earlier treatment initiation.   By 2001 the DHHS guidelines 
swung back to recommending treatment only for asymptomatic patients with CD4+ 
<200/mm3/viral load > 100,000 copies/ml (Figure 2).  The quest for new approaches 
to treatment included a paradigm-shifting large randomised clinical trial known as the A
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SMART (“Strategies for management of antiretroviral therapy”) study which 
randomized patients either to continuous therapy or a drug conservation arm with 
either planned deferral of initial therapy until CD4+ < 250 or CD4+ guided 
discontinuation of treatment[6]Study results showed without question that those 
randomized to drug conservation endured significantly more AIDS and collective 
non-AIDS morbidity and mortality compared to those on continuous therapy, and put 
to rest the notion of “drug holidays” as a viable solution to pill fatigue and toxicities 
to rest[6].  
 
More recent cohort studies have also suggested a potential benefit of earlier therapy 
on survival [7] and an on-going randomized controlled study, the “START study” is 
examining the impact of earlier treatment in asymptomatic individuals with CD4+ T 
cell count > 500/mm
3
 on HIV and non-HIV events is expected to completed by 
2016[8].  
 
 Treatment success in experienced populations now approaches that seen in treatment 
naïve populations and this relates to development of new classes of drugs such as 
integrase strand transfer inhibitors, 2
nd
 generation NNRTIs, longer acting PIs with 
fewer toxicities and heat stable ritonavir. 
 
The realization that there would be no immediate cure for HIV highlighted the need to 
scale-up preventive approaches.  It is estimated that more than 50% of HIV 
transmission results from the 25% of individuals that are unaware of their HIV status 
and that > 50% of HIV diagnosed individuals are not engaged in medical care [9].  
The HPTN-052 study was a landmark randomized double blind controlled study that A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
randomized the HIV positive individual in largely heterosexual sero-discordant 
couples to immediate versus deferred ART until CD4+ T cell count <350/mm
2
. The 
results confirmed only one transmission event in the treatment arm (linked to 
transmission before treatment began) with 27 linked transmission events occurring in 
the deferred therapy arm (p<0.001).  Individuals in the immediate therapy arm 
showed a significantly longer time to develop AIDS and tuberculosis events [10]. 
This study has been a strong driver of the global homogenization of HIV treatment 
guidelines supporting earlier and unselective initiation of ART across the DHHS, IAS 
and WHO guidelines (Figure 2).  Early ART approaches in the resource poor settings 
were also modelled to be cost-effective over the life-time of serodiscordant couples 
[11]. 
 
The treatment of HIV has presented many pharmacological challenges and triumphs.    
This review reflects on these and the future of HIV treatment.  
 
 
 
Pharmacological Challenges and Triumphs  
Pharmacoenhancement/Pharmacokinetic boosting 
Early PIs needed to be dosed three times daily either fasting or with a significant meal 
and/or liquid intake, amounting to daily pill burdens of up to 22.  Even with 
adherence to these stringent criteria, achievable drug exposures were often perilously 
close to the minimum concentration required for viral inhibition.  Imperfect 
adherence, malabsorption or undetected drug interactions placed patients at risk for 
sub-therapeutic exposures and risk of virologic breakthrough and development of A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
resistance.  A significant advance in treatment was achieved with the concept of 
pharmacoenhancement with ritonavir.   The demonstration that low dose ritonavir 
(100-200 mg daily) could be used to increase the systemic bioavailability of the 
accompanying CYP3A4 substrate PI by increasing total AUC, half-life, and minimum 
concentrations and decreasing PK variability was a major advance[12].  This allowed 
simplification to once or twice daily administration and led to improved patient 
adherence and virologic outcomes, particularly in treatment experienced patients 
where boosted regimens had the ability to overcome low-level PI resistance[13-16].  
 
A new pharmacokinetic enhancer, cobicistat was designed to inhibit the CYP3A 
enzyme without antiretroviral activity.  At a dose of 150 mg it was found to exhibit 
similar CYP3A4 activity to ritonavir 100 mg.  Similar to ritonavir, cobicistat also 
inhibits CYP2D6 and the transporter p-glycoprotein but not CYP1A2, 2C9 or 2C19.   
The integrase inhibitor elvitegravir is a CYP3A4 substrate and is coformulated with 
cobicistat in combination with tenofovir and FTC to allow once daily dosing as a 
single pill [17, 18].   Cobicistat has also been shown to be an effective booster of 
atazanavir, and a co-formulated product with darunavir is currently in development. 
Studies have suggested that cobicistat shares gastrotinestinal and metabolic toxicities 
with ritonavir. 
 
The concept of pharmacokinetic enhancement has also been applied to hepatitis C 
(HCV) antiviral therapy where ritonavir is being co-administered with ABT-450 and 
danoprevir in phase 2 and late phase 3 studies to optimize PK and simplify dosing[19, 
20].  Drawbacks to the use of pharmacokinetic boosters include increased risk of 
undesirable interactions with concomitant medications. A
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Therapeutic Drug Monitoring (TDM) 
Measuring antiretroviral plasma concentrations allows individualization of drug 
dosing to optimize exposure and decrease the risk of toxicity or treatment failure.  PIs 
and NNRTIs are considered especially ideal candidates for TDM due to high inter- 
and intra-patient variability, susceptibility to drug interactions, and identification of 
minimum concentrations for efficacy. Other drugs are less suited for TDM due to 
varying drug distribution/site of action, and plasma concentration measurements may 
not be as well correlated with response.  For instance, TDM of NRTIs is limited by 
the practical difficulties of measuring intracellular concentrations.  Other barriers to 
TDM include cost, accessibility, and variable inter- and intra-laboratory 
standardization.   
 
Early prospective, randomized studies in treatment-naïve populations suggested 
benefit with indinavir and nelfinavir TDM [21, 22].  The clinical benefit of TDM in 
was shown in a retrospective study in 137 patients.  Improved clinical outcome was 
demonstrated in 16/20 (80%) of patients who underwent TDM-guided dose 
adjustment; 10 patients experienced resolution of drug-related toxic effects and 6 
patients had improved virologic response with viral load reductions of greater than 1 
log [23].Subsequent negative studies in treatment-experienced patients were limited 
by inclusion of patients already virologically suppressed at baseline, use of target 
concentrations that were inadequate for drug-resistant virus, delayed implementation 
of TDM, limited follow-up, low rates of adherence to TDM recommendations and 
lack of statistical power [24, 25] HIV treatment guidelines have endorsed the use of 
ART TDM in the management of special populations such as those with PK variation A
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or at high risk for drug interactions including patients with concomitant tuberculosis, 
opportunistic infections,  hepatitis B or C co-infection, children, pregnancy, aging, 
cancer, organ transplant and suspected nonadherence or virological failure)[26-28].   
 
 Understanding and avoiding drug-drug and food-drug interactions 
Drug interactions continue to be a significant challenge in the management of patients 
with HIV.  In the early days, NRTIs in use were associated with many side effects and 
overlapping toxicities with drugs used to treat opportunistic infections (Table 2).    
With the arrival of PIs and NNRTIs and the advent of pharmacokinetic boosting, drug 
interactions became more complex due to the numerous effects on CYP450 enzymes 
and transporters, thus making these antiretrovirals frequent perpetrators and victims of 
drug-drug interactions (Table 2).    
Older HIV patients have more co-morbidities and are at risk to be on several 
medications heightening the risk of drug-drug interactions [29, 30], complicating the 
treatment of HIV and concurrent non-AIDS conditions.  In addition, clinically 
significant interactions have been reported between ART and non-oral medications, 
such as inhaled, topical or injectable corticosteroids[31-33].  Complementary and 
alternative medicine (CAM), over-the-counter (OTC) products, and recreational 
agents may further place patients at risk for unidentified drug interactions [34-36].  
These challenges should not be overlooked in resource poor settings where increased 
access to protease inhibitors is becoming more common. A recent report highlighting 
the risk of ergotism secondary to PI therapy and concomitant OTC ergotamine use in 
Thailand illustrates this concern[37]. Identification of drug interactions requires 
routine medication reconciliation, ideally at each patient clinic visit or at least once a 
year, and at any interface of care such as hospital admission or discharge, or A
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consultations with other specialists or health care professionals.  Patients should use a 
single pharmacy to ensure comprehensive and current medication profiles.  Drug 
interactions can be managed through adjustment of drug dose(s) or frequency of 
administration, substitution with an alternative agent, heightened clinical, laboratory 
and drug level monitoring, or temporary or permanent discontinuation of non-critical 
therapies.   
 
Clinicians are encouraged to consult an HIV pharmacist and utilize specialized 
resources that are regularly updated to aid in management of potential drug 
interactions since product monographs and standard references may not always 
contain newly identified data.  Recommended websites include those run by the 
University of Liverpool Pharmacology Group [38], The University of California, San 
Francisco [39], and Toronto General Hospital [40]. 
 
Adherence/New Drug Formulations 
While taking >80% of medication is considered excellent adherence for most chronic 
diseases, it became clear in the early days of HAART that >95% to ART was required 
to reliably achieve virologic suppression [5, 41]  The first agent to be approved for 
treatment of HIV was AZT, which was originally dosed at 200 mg every 4 hours 
based on its short plasma half-life.  However, after realization that intracellular 
concentrations were more relevant than plasma concentrations for NRTIs, AZT 
dosing was later modified to 300 mg BID, and most drugs in this class are now dosed 
once daily.  Recent progress in overcoming ART adherence challenges has included 
development of improved drug formulations which lack food and storage 
considerations, lower pill burden, and more favorable short and long-term toxicity A
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profiles. For instance, development of an enteric-coated didanosine capsule 
formulation removes the risk for cation/buffer interactions, while extended release 
formulations for stavudine and nevirapine allow once daily dosing.  Fosamprenavir, a 
pro-drug of amprenavir, is associated with significantly reduced daily pill burden, 
dosing schedule and pill size compared to its predecessor.  More recently, 
development of a heat-stable version of ritonavir has allowed for increased 
convenience and patient acceptability.   
 
Fixed-dose combination (FDC) products are available for preferred NRTI backbone 
regimens, the boosted PI combination of lopinavir/ritonavir, and a soon-to be released 
combination of darunavir/cobicistat.  Adherence and ART success rates have 
improved [42, 43]. In 2006, the approval of co-formulated tenofovir/FTC/efavirenz 
allowed for the first “one pill, once a day” regimen.  There are currently three FDA-
approved single-tablet regimens (STRs) which allow for single tablet once daily 
dosing:  FTC-tenofovir-efavirenz, FTC-tenofovir-rilpivirine and FTC-tenofovir-
elvitegravir-cobicistat. A fourth STR of abacavir, 3TC and dolutegravir is pending 
approval. 
 
FDC and STRs do not allow the flexibility to individualize dose, and an additional 
caveat is the genericization of antiretrovirals which may provide financial incentives 
to move away from the more expensive STRs in the developed world where generic 
STRs are not available. 
 
Treatment Toxicity and Regimen Simplification A
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With the success of modern cART and the trend towards earlier treatment initiation, 
long term treatment toxicities including psychiatric, metabolic, renal, bone and 
cardiovascular issues are increasingly being recognized as important contributors to 
treatment discontinuation and/or increased morbidity, especially in the aging HIV 
population.  The search for safer and better tolerated ART options continues.  One 
agent in late-stage development is tenofovir alafenamide (TAF), which is a prodrug of 
tenofovir disoproxil fumarate.  TAF at a dose of 25 mg provides enhanced delivery of 
tenofovir to lymphatic tissues, which results in significantly enhanced concentrations 
of tenofovir diphosphate in peripheral blood mononuclear cells (approximately 5-fold 
increase) and approximately 90% lower circulating tenofovir compared to 
administration of a standard 300 mg dose of tenofovir disoproxil [44]. When single-
tablet-regimens of elvitegravir, cobicistat, emtricitabine and either tenofovir 
disoproxil or tenofovir alafenamide were compared in treatment naïve subjects, the 
TAF treatment arm showed similar rates of viral suppression at week 48 and 
significantly lower bone mineral density change and lesser increase in serum 
creatinine compared to the tenofovir disoproxil-containing STR arm[45]. 
 
More recently, interest has focused on strategies of switching virologically suppressed 
patients to better tolerated or simplified regimens in order to enhance long term 
adherence and treatment perseverance.  Switches from efavirenz or boosted PI-based 
regimens to rilpivirine-tenofovir-emtricitabine single tablet regimen have led to 
improvements in toxicities including CNS and fasting lipids, respectively, while 
maintaining virologic suppression [46, 47]. 
Switching from boosted PIs or NNRTIs to an InSTI-based regimen in virologically 
suppressed patients has been similarly successful [48-50]. However, as illustrated by A
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the results of the SWITCHMRK study [46, 51] inclusion of agents with a high barrier 
to resistance is critical to maintaining continued viral suppression, particularly in 
patients with pre-existing treatment resistance mutations.  
 
 
Sanctuary Sites    
Increased knowledge regarding the distribution of antiretrovirals into various 
compartments and sanctuary sites has helped to individualize clinical treatment. In the 
pre-HAART era, AIDS-associated dementia was a frequent and devastating condition 
where high dose and poorly tolerated oral or intrathecal AZT was the only available 
strategy to control HIV replication in the CNS.  AIDS-associated dementia has 
significantly decreased with cART, but there is increasing concern regarding more 
subtle HIV-associated neurocognitive disorders (HAND), even in patients without 
detectable HIV in plasma.  The development of HAND may be correlated with how 
efficiently various antiretrovirals penetrate the CNS.  Early studies yielded 
inconsistent data regarding the association between cumulative CNS penetration 
effectiveness (CPE) scores and neurocognitive outcome [52]. A recent study suggests 
that this approach may have benefit in protecting against cognitive deterioration [53]. 
Further research in this area is needed. 
 
Physiological changes associated with pregnancy may affect PI PK and TDM and/or 
dose adjustment is recommended in the second or third trimester to ensure therapeutic 
antiretroviral concentrations, particularly at the time of delivery in order to minimize 
the risk of vertical HIV transmission.  Maternal genital tract viral burden has been 
shown to be an independent factor associated with HIV transmission and adequate A
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genital tract antiretroviral exposures may play a role in prevention. This concept was 
illustrated in an unfortunate case of transmission of multidrug-resistant virus to a 
newborn in a treatment-experienced  but virologically suppressed woman on salvage 
ART where enfuvirtide was the only active agent which poorly penetrated the genital 
tract [54]. 
 
The strategy of utilizing antiretroviral therapy in individuals at high risk of acquiring 
HIV (i.e., pre-exposure prophylaxis or PrEP) represents another significant milestone 
in HIV therapeutics.  In 2012, tenofovir/emtricitabine became the first regimen to 
receive an FDA indication for PrEP.    Eight PrRP studies have been conducted 
employing topical and oral formulations of ART. The study populations for these 
studies mainly consisted of African women at high risk of heterosexual HIV 
acquisition (CAPRISA 004, FEM-PrEP, Partners PrEP, TDF2, VOICE/MTN 003 and 
FACTS 001).  However they also involved African heterosexual men in two studies 
(Partners PrEP, TDF2), men who have sex with men (from the Americas, Thailand 
and South Africa) in the iPrEx study and Thai male injecting drug users in the 
Bangkok Tenofovir Study. The effectiveness from these studies ranged from 75% 
reduction in HIV-1 incidence in the Partners PrEP study with FTC/TDF prophylaxis 
compared to no reduction seen in the FEM-PrEP study (also using FTC/TDF). 
Notably, the success with the prophylactic therapies is dependent on the degree of 
adherence to the study regimens. The iPrEx study demonstrated that participants 
having detectable drug concentrations were strongly associated with a significantly 
lower risk for HIV-1 acquisition (73% efficacy with ≥ 90% adherence)[55].  
Efficacy results have varied across these PrEP trials and have been significantly lower 
in those involving women. This also highlights the potential differences in A
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antiretroviral PK/PD in the male and female genital tracts alongside the significant 
influence of therapy adherence.  
Localized delivery systems such as intravaginal rings [56, 57] show some promise, 
however, more insight into pharmacological limitations is needed to develop effective 
PrEP options. 
 
Pharmacogenomics to identify/minimize toxicity 
A hypersensitivity syndrome associated with the NRTI abacavir was first described in 
the pre-marketing phase of drug development and was characterized by fever, 
malaise, gastrointestinal symptoms and later rash on first exposure with severe 
hypotension and shock on rechallenge[58, 59]. The discovery of an association 
between abacavir hypersensitivity and the HLA class I allele HLA-B*57:01 and its 
translation into routine HIV clinical practice as a guideline endorsed preventive 
screening strategy has created a roadmap for pharmacogenomic translation [58, 
60],Since the introduction of routine HLA-B*57:01 screening prior to abacavir 
prescription, true immunologically mediated abacavir hypersensitivity has 
disappeared [61]. Other ART toxicity-pharmacogenomic relationships that have been 
explored in detail and reproduced amongst different groups include CYP2B6 and 
UGT1A1 polymorphisms and efavirenz exposure/pharmacokinetics and atazanavir 
associated unconjugated hyperbilirubinemia respectively.[62]  Some studies have 
suggested relationships between genetic polymorphisms and discontinuation related to 
ART related adverse events [63].  One small study successfully dose-reduced 
efavirenz in patients with the CYP2B6 516 G T polymorphism using adjunctive 
TDM [64]. The CYP2B6 516 G T polymorphism is particularly prevalent in Black A
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African and African American populations (up to 20%) and PK studies have 
demonstrated higher exposure in these populations[65]. 
 
Future Promises 
Throughout the progress of the last three decades the primary goals of ART remain 
largely unchanged: to suppress HIV viral load, to restore immune function, to 
preserve future treatment options and to improve quality and quantity of life.  Newer 
considerations have included the control of HIV transmission (“treatment as 
prevention”), consideration for managing and preventing non-AIDS as well as AIDS 
morbidity and the ultimate goal of HIV eradication or functional cure. 
Emerging data has suggested that treatment as prevention approaches are cost-
effective [11] however there is a massive demand for scale-up and continued 
improvements in cost-efficiency will be necessary to achieve broader access to 
antiretroviral therapy. In 2012, 9.7 million people with HIV were accessing ART and 
this was a 1.6 million increase from 2011[66]. It has been estimated that broader 
access to treatment following current HIV treatment guidelines would avoid 19 
million new HIV infections by 2025.  The immediate goal by UNAIDS is to achieve 
coverage of 15 million by 2015.  Significant efforts and achievements in decreasing 
the cost of ART and HIV testing.  This has included process chemistry improvement 
to ART drug manufacturing by generic companies, reformulation, dose optimization 
and extension of shelf-life [67]. For example process chemistry was able to reduce the 
number of manufacturing steps for efavirenz from four to two resulting in a 75% price 
decrease from $240/patient/year in 2006 to $60/patient/year in 2011[68]. Similar 
process chemistry improvements in manufacturing have been applied to tenofovir DF 
and are in development for darunavir. A
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An exciting new pharmacological development has been that of nanotechnology to 
develop long-acting injections of antiretroviral drugs that could be administered once 
monthly [69, 70]. Current injectable nanoformulations are under study including the 
second generation NNRTI rilpivirine and a new long-acting integrase inhibitor (GSK-
1265744).  GSK-1265744, a dolutegravir analogue, is detectable in plasma out to 48 
weeks following a single injection.  These two drugs have been studied in 
combination in Phase I studies examining PK and safety.  Forty-eight week results 
from a Phase IIb study of rilpivirine plus oral GSK-1265744 as maintenance therapy 
showed similar virologic suppression rates compared to standard efavirenz-based 
treatment[71].[ These promising results support the development of using rilpivirine 
and GSK-1265744 as a monthly injectable regimen, which may help combat 
adherence challenges. Use of these injectable drugs are also being explored in the 
developing world as a preventive strategy.  
 
Although ART controls actively replicating HIV, latent HIV persists in resting 
memory CD4+ T cells and this remains the major barrier to HIV eradication or cure.  
Treatment intensification studies with multiple antiretroviral agents including CCR5 
and integrase inhibitors have not resulted in a decreased size of the HIV reservoir or 
prevented recurrent HIV viremia off ART[72]. Short-course ART during primary 
infection has been shown to have immunological and virological benefit and may 
reduce the size of the latent reservoir of HIV, protect HIV specific cellular and 
humoral responses and restrict the diversification of HIV, but is unlikely to effect HIV 
cure [73]. The promise of HIV eradication was fuelled by the “Berlin patient” who 
received an allogeneic stem cell transplantation from an HLA-matched donor 
homozygous for a 32 bp deletion in the CCR5 allele 6 years ago and has remained A
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free of recrudescent HIV replication off cART[74].  The definition and quantification 
of HIV eradication has not been precisely defined; however 5 years after cART 
withdrawal there has been significant waning of HIV specific T-cell responses and no 
evidence of active HIV replication in this patient[75].   Experimental pharmacological 
strategies to bring HIV out of latency have been examined in early phase studies in 
humans.  This has included the use of inhibitors of histone deacetylase (HDAC) such 
as vorinostat which has shown some promise in increasing cell associated HIV RNA, 
although cells do not die on reactivation of latent HIV meaning that it is likely that a 
combination of pharmacological, gene and therapeutic vaccine approaches will be 
necessary to effect eradication [76, 77].  
 
Conclusions 
HIV treatment has evolved from gruelling regimens with high pill burden, 
inconvenient dosing, treatment limiting toxicities, food and drug interactions, 
incomplete viral suppression and emergence of drug resistance to manageable 1-2 pill 
once daily regimens that can be initiated in early HIV disease and continued with 
control of viral replication over much of an individual’s life span.  Life expectancies 
of those who have achieved immune reconstitution and remain virologically 
suppressed should be close to normal.  Pharmacological advances in the study and 
treatment of HIV have been at the frontier of science.  Examples include 
pharmacogenomic discovery and translation (HLA-B*57:01 screening to prevent 
abacavir hypersensitivity), drug class and formulation discovery (FDC, long-acting 
injectable nano-formulations), pharmacokinetic enhancement and the management 
and provision of decision support for complex drug-drug and food-drug interactions.  
Current and future challenges include the continued globalization of ART through A
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scale-up and continued improvements in cost-efficiency, engagement and retention of 
patients in care, new immunological and pharmacological approaches to prevention 
and the science and translation of HIV eradication strategies.  
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Table 1.  What to Start:  Specific agents recommended as first line treatment and 
difference between the guidelines are highlighted showing the eventual convergence 
of first line recommendations between the developing and developed world. 
 
Year DHHS EACS WHO 
                              Preferred combination                   ART Regimen Recommended ART  Regimen 
1998/06 AZT/3TC (fixed dose 
combination(FDC)),AZT/ddI, 
AZT/ddC, AZT/ddI, D4T/ddI, 
D4T/3TC 
                 + 
IDV/SQV/NFV/RIT or SQV/RTV 
  
1998/12 As above + addition of EFV as the third 
agent 
  
1999 As above with addition of ddI/3TC as 
NRTI combination 
  
2000 As above but high dose RTV removed 
as third agent and ddI/3TC removed as 
NRTI combination 
  
2001 As above with addition of RTV boosted 
PI regimens as third agents 
(IDV/r,SQV/r, LPV/r (FDC PI)) 
  
2002   AZT/3TC 
+ 
EFV, PI/r, NFV or ABC 
2003/07 3TC + (d4T,AZT or TDF) + EFV 
Or 
3TC + (d4T or AZT) + LPV/r 
  
2003/11 As above but addition of FTC as 
alternative to 3TC in combination with 
(d4T,AZT or TDF) + EFV 
Weighed pro’s and con’s of 
NNRTI based versus PI based 
with Triple NRTI (AZT-3TC-
ABC) regimens 
AZT or d4T + 3TC 
+ 
NVP or EFV 
2005 As above with deletion of d4T from 
first line treatment and addition of FTC 
as alternative to 3TC in combination 
with AZT/LPV/r 
  
2006 AZT/3TC or TDF/FTC (both FDC) 
+ 
 
EFV,ATV/r,FPV/r or LPV/r 
  
2008/1 ABC/3TC
+
 or TDF/FTC (both once 
daily FDC) 
+ 
EFV,ATV/r,FPV/r or LPV/r 
  
2008/11 TDF/FTC 
+ 
EFV,ATV/r.FPV/r,LPV/r,DRV/r 
ABC/3TC
+
 or TDF/FTC 
+ 
EFV or NVP or a PI/r 
(FPV/R,LPV/r,SQV/r) 
 
2009 TDF/FTC 
+ 
EFV or ATV/r or DRV/r or RAL 
 AZT or TDF + 3TC or FTC 
+ 
EFV or NVP 
2012 As above   
2013/02 TDF/FTC 
+ 
EFV or ATV/r or DRV/r or RAL 
ABC/3TC+ or TDF/FTC 
+ 
EFV or RPV (VL<100,000 
TDF + 3TC or FTC 
+ 
EFV A
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copies/ml)  OR  ATV/r or 
DRV/r OR RAL 
2013/10 As above, added TDF/FTC/EVG/co 
(if Clcr>70 mL/min) and DTG plus 
TDF/FTC or ABC/3TC as preferred 
regimens 
  
 
+
ABC used only in HLA-B*57:01 negative individuals 
ABC (abacavir), AZT (zidovudine), ATV (atazanavir), ddC (zalcitabine), ddI (didanosine), 
d4T(stavudine), DRV (darunavir), EFV (efavirenz), FPV (fosamprenavir), FTC (emtricitabine), 3TC 
(lamivudine), IDV (indinavir), NVP(nevirapine), RAL (raltegravir), r (boosting dose ritonavir 100-200 
mg daily), RPV (rilpivirine), RTV (high-dose ritonavir), SQV (saquinavir), WHO (World 
Organization), EACS (European AIDS Clinical Society), DHHS (Department of Health and Human 
Services) 
 
 
 
 
 
Table 2:  Actual and Potential Drug Interactions in HIV (attached) 
 
 
Figure 1:  Timelines of Antiretroviral Development 
 
The time course of development of > 25 drugs across 5 different classes over the last 
27 years is highlighted according to the FDA approval date. Those that are no longer 
in use or available have illustrated with an “X” through them. 
 
Figure 2 Convergence of  HIV Treatment Guidelines in the Developed and 
Developing World. Changes in recommendations on when to start ART in 
asymptomatic HIV-infected individuals based on CD4+ count criteria.  The 
DHHS, European and WHO guidelines over time showing the fluctuations in 
recommendations which in the developed world represented a change from the initial 
optimism of “hit hard hit early” in 1998 to the reality of challenging high pill burden 
combinations.  In the developing world the trend has moved upwards largely based on 
increased availability of ART and HIV care in the developing world. The DHHS 
guidelines have now moved to an evidence based approach where treatment is 
recommended in all asymptomatic individuals but with various grades of evidence. 
The European guidelines have been more conservative awaiting the results of the 
START study a randomized double blinded study of treatment initiation in treatment 
naïve asymptomatic HIV-infected individuals with CD4+ T cell count  >500 or < 
500/mm
3
.  Although there are differences between guidelines all agree and 
recommend earlier ART initiation regardless of CD4+ count in high risk patients 
groups such as those with co-morbidities such as co-infection with hepatitis B or C, 
HIV-associated nephropathy, rapid decline in CD4+, pregnancy and in sero-
discordant partner situations).       
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Table 2:  Actual and Potential Drug Interactions in HIV 
 
 Pre- and Early HAART Era Contemporary cART Era 
 Effect HIV drug(s) Drugs for concomitant 
OIs, etc. 
Effect HIV drug(s) Concomitant Drugs/ 
Diseases 
Pharmacodynamic Bone marrow 
suppression 
AZT Sulfa drugs, 
ganciclovir, foscarnet, 
amphotericin B 
Bone turnover Tenofovir  Osteoporosis 
 Hepatotoxicity PIs, NNRTIs Antimycobacterials Hepatotoxicity PIs, NNRTIs Hepatitis B/C 
 Pancreatitis ddI, ddC, d4T Pentamidine, foscarnet Metabolic 
disorders 
PIs, some 
NNRTIs/NRTIs 
Cardiovascular disease, 
diabetes 
 Peripheral 
neuropathy 
“ Isoniazid, vinca 
alkaloids 
Nephrotoxicity Tenofovir NSAIDs, nephrotoxins, 
renal impairment 
    QT 
prolongation 
Rilpivirine, 
some PIs (eg., 
saquinavir, 
fosamprenavir) 
Antiarrhythmics, 
antipsychotics, 
citalopram/escitalopram, 
macrolides, methadone, 
moxifloxacin, 
pentamidine, telaprevir,  
congenital long QT 
syndrome 
Pharmacokinetic Absorption   Absorption   
  Gastric pH ddI (basic) Ketoconazole, 
itraconazole (acidic) 
 Gastric pH Atazanavir, 
rilpivirine 
(acidic) 
Antacids, H2RA, proton 
pump inhibitors 
  Indinavir, 
delavirdine 
(acidic) 
Antacids, H2RA, 
proton pump inhibitors 
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 Pre- and Early HAART Era Contemporary cART Era 
 Effect HIV drug(s) Drugs for concomitant 
OIs, etc. 
Effect HIV drug(s) Concomitant Drugs/ 
Diseases 
  Chelation  ddI  Quinolones   Chelation  Integrase 
inhibitors 
Antacids, oral calcium or 
iron  supplements and 
buffered medications 
  Food Indinavir, ddI, 
efavirenz 
(empty 
stomach); PIs 
(high fat 
meal) 
  Food Efavirenz 
(empty 
stomach), PIs, 
rilpivirine, 
etravirine, 
elvitegravir 
(with a meal)  
 
 Metabolism PIs, NNRTIs Rifamycins 
Anticonvulsants 
Metabolism 
 
PIs, 
elvitegravir/ 
cobicistat, 
NNRTIs,  
(perpetrators) 
 Antiinfectives:  directly 
acting agents for 
hepatitis C, rifamycins, 
azole antifungals 
 Antineoplastics:  
etoposide, vinca 
alkaloids, tyrosine 
kinase inhibitors, 
paclitaxel, docetaxel, 
others 
 Cardiovascular agents:  
statins, calcium 
channel blockers 
 Corticosteroids (oral, 
inhaled, topical, 
injection), hormonal 
contraceptives A
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 Pre- and Early HAART Era Contemporary cART Era 
 Effect HIV drug(s) Drugs for concomitant 
OIs, etc. 
Effect HIV drug(s) Concomitant Drugs/ 
Diseases 
 Psychotropics:  
benzodiazepines, 
antidepressants, 
anticonvulsants 
 Recreational 
drugs/narcotics:  
MDMA (ecstasy), 
methadone, PDE5 
inhibitors 
 Transplant drugs:  
cyclosporine, 
tacrolimus, sirolimus 
 Misc:  ergot 
derivatives 
    Metabolism PIs, NNRTIs, 
cobicistat, 
elvitegravir/ 
cobicistat, 
maraviroc,  
(victims) 
 Antiinfectives:  directly 
acting agents for 
hepatitis C, rifamycins, 
azole antifungals 
 Anticonvulsants 
 CAM:  St. John’s wort, 
ginko biloba, activated 
charcoal 
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